Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | ACE | P12821 | 1/20 | 0.32 |
| ▸ | CPA1 | P15085 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1287222 | 1.00 | KDM4E (0.32) | KDM4EALDH1A1TSHRMMEACE | |
| SCHEMBL1287220 | 0.76 | — | — | |
| SCHEMBL13248610 | 0.76 | — | — | |
| SCHEMBL7772973 | 0.74 | — | — | |
| SCHEMBL1287248 | 0.74 | — | — | |
| SCHEMBL9168326 | 0.74 | FOLH1 (0.34) | KDM4EALDH1A1TSHRMMEACE | |
| SCHEMBL1287361 | 0.74 | CYP2D6 (0.34) | KDM4EALDH1A1TSHRMMEACE | |
| SCHEMBL9168323 | 0.74 | FOLH1 (0.34) | KDM4EALDH1A1TSHRMMEACE | |
| SCHEMBL12477657 | 0.73 | — | — | |
| SCHEMBL1287186 | 0.72 | MME (0.36) | KDM4EALDH1A1TSHRMMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3224268-A1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana BioMed Limited (GB) | 2017-10-04 | — | — | EP | claimed |
| WO-2016083830-A1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NUCANA BIOMED LIMITED (GB) | 2016-06-02 | — | — | WO | claimed |
| US-10570168-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds | NuCana plc (GB) | 2020-02-25 | — | — | US | disclosed |
| EP-3224268-A1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NuCana BioMed Limited (GB) | 2017-10-04 | — | — | EP | disclosed |
| US-20170253629-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NUCANA BIOMED LIMITED (GB) | 2017-09-07 | — | — | US | disclosed |
| EP-2658857-B1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | INHIBITEX INC (US) | 2016-11-02 | — | — | EP | disclosed |
| WO-2016083830-A1 | NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | NUCANA BIOMED LIMITED (GB) | 2016-06-02 | — | — | WO | disclosed |
| US-9351989-B2 | Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections | INHIBITEX, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20140140955-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2014-05-22 | — | — | US | disclosed |
| EP-2658857-A2 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | Inhibitex, Inc. (US) | 2013-11-06 | — | — | EP | disclosed |
| WO-2012092484-A2 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | INHIBITEX, INC. (US) | 2012-07-05 | — | — | WO | disclosed |
| WO-2012048013-A2 | PHOSPHORODIAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INJECTIONS | INHIBITEX, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| EP-2385951-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | University College Cardiff Consultants, Ltd. (GB) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254856-A1 | MOBILE TERMINAL AND METHOD OF CONTROLLING OPERATION OF THE MOBILE TERMINAL | LG ELECTRONICS INC. (KR) | 2011-10-20 | — | — | US | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | KDM4E 4140/4885ALDH1A1 4139/4885TSHR 4198/4885 |
| US-10570168-B2 | 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds | MTAP, RNMT, ADA | KDM4E 1394/4885ALDH1A1 2162/4885TSHR 4795/4885 |
| US-20140140955-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHOROAMIDATE AND PHOSPHORODIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | PNP, UMPS, UPP1 | KDM4E 2806/4885ALDH1A1 2369/4885TSHR 3467/4885 |
| US-20170253629-A1 | 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS | MTAP, ADA, RNMT | KDM4E 1420/4885ALDH1A1 2194/4885TSHR 4793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.